Expression profiles analysis reveals an integrated miRNA-lncRNA signature to predict survival in ovarian cancer patients with wild-type BRCA1/2
Metrics: PDF 691 views | HTML 1167 views | ?
Liyuan Guo1, Yan Peng2, Yuanyuan Meng1, Yunduo Liu1, Shangshang Yang1, Hong Jin1 and Qi Li1
1Gynecological Cancer Department, Harbin Medical University Cancer Hospital, Harbin 150081, China
2Disease Prevention Center, First Affiliated Hospital of Heilongjiang University of Chinese Traditional Medicine, Harbin 150040, China
Qi Li, email: email@example.com
Keywords: BRCA1/2, ovarian cancer, microRNA, long non-coding RNA, prognosis
Received: June 08, 2017 Accepted: June 28, 2017 Published: July 26, 2017
Emerging evidence shows that dysregulated expression of microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) were closely linked with disease progression, including cancers. However, the joint predictive power of miRNAs and lncRNAs in prognosis for ovarian cancer (OV) patients with wild-type BRCA1/2 is as yet unknown. In this study, we sought to assess the joint predictive power of miRNAs and lncRNAs by integrating miRNA and lncRNA expression profiles and clinical data of 281 OV patients with wild-type BRCA1/2 from The Cancer Genome Atlas (TCGA) project. Finally, we identified an integrated miRNA-lncRNA signature composing of two lncRNAs (LINC01234 and CCDC144NL-AS1) and two miRNAs (miR-637 and miR-129-5p) which can effectively classify OV patients with wild-type BRCA1/2 into groups with the good and poor outcome. The prognostic value of the integrated miRNA-lncRNA signature was validated in the testing cohort and entire TCGA cohort. Multivariate analysis demonstrated the independence of the integrated miRNA-lncRNA signature of known other clinical factors. Further analysis suggested that patients who were in the low-risk group based on the signature achieved a better CR from platinum-based chemotherapy compared with patients in the high-risk group. Our results indicated that this integrated miRNA-lncRNA signature may have important clinical implications for risk stratification of ovarian cancer patients with wild-type BRCA1/2.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.